Navigation Links
Spectranetics Receives Reimbursement Approval in Belgium for Lead Removal and Peripheral Atherectomy Products
Date:10/9/2007

rial blockages in the legs and heart, as well as scar tissue encapsulating pacing and defibrillation leads. For more information visit http://www.spectranetics.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties may include increasing price and product competition, increased pressure on expense levels resulting from expanded marketing and clinical activities, uncertain success of the Company's strategic direction, dependence on new product development, intellectual property claims of third parties, availability of inventory from suppliers, the receipt of FDA approval to market new products or applications and the timeliness of any approvals, the potential size of market opportunities associated with new products, market acceptance of new products or applications, product defects, unexpected delays or costs associated with the Company's relocation and consolidation of its headquarters and manufacturing operations, price volatility due to the initiation or cessation of coverage, or changes in ratings, by securities analysts. For a further list and description of such risks and uncertainties that could cause the actual results, performance or achievements of the Company to be materially different from any anticipated results, performance or achievements, please see the Company's previously filed SEC reports. Spectranetics disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether as a result of new information, future events or otherwise.

COMPANY CONTACT:

Spectranetics Corporation

Guy Childs, Ch
'/>"/>

SOURCE Spectranetics Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Infant receives first bloodless liver transplant
2. British MPs Say Prostate Cancer Receives Low Priority in the NHS
3. Fifth US Patient Receives Artificial Heart
4. Northfield Labs Receives FDA Comments
5. Abbott Receives CE Mark Certification
6. Zactima Receives Fast Track Designation By The FDA
7. East London Receives World Class New Private Hospital Facility
8. Brinda Karat Receives Legal Notice over Ramdev Issue
9. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
10. Medtronic’s Insulin Pump Receives Regulatory Approva
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Boston University School of Medicine,s (BUSM) Pulmonary ... from the National Heart, Lung, and Blood Institute ... patients with lung disease. , Darrell Kotton, ... Gustavo Mostoslavsky, MD, PhD, assistant professor of medicine, ... award. Together Kotton and Mostoslavsky lead a multicenter ...
(Date:12/16/2009)... Global Market Expansion , ... Ramat-Gan, Israel (PRWEB) December ... to Web sites and companies, today announced a record year of ... Since its launch on July 2008, Kampyle has processed more than ... more than 30,000 customers in 191 countries., , ,Kampyle pioneered the ...
(Date:12/16/2009)... -- For ages, people from around the world have ... soothing waters have a reputation that dates back over ... miracles. Now, with the introduction of two bath salt ... the legendary benefits of Dead Sea salt in their ... all-natural Dead Sea salt and essential oils - but ...
(Date:12/16/2009)... WILMINGTON, Delaware, December 16 While ... outsource their accurate forecast models,for new and ... provides,integrated patient-based forecast solutions to various players. ... I, phase II, as well as phase,III. ... launch, product life cycle,management, market entry strategy, ...
(Date:12/16/2009)... has run marathons, competed in triathalons and appeared on ... -- Sarah Reinertsen likes to think of herself as part ... world is how the 34-year-old triathlete likes to describe herself. ... her speaking to packed school auditoriums or posing nude with ... the cover of the latest ESPN Body Issue. ...
Breaking Medicine News(10 mins):Health News:Boston University School of Medicine's pulmonary center receives $1.4 million grant 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 2Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 3Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 4Health News:Kampyle Experiences Record Growth in 2009 with 25,000 New Customers 5Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 2Health News:SaltWorks Launches Two All-Natural Bath Salt Lines Featuring Therapeutic Salt from the Dead Sea 3Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 2Health News:MarketsandMarket's Integrated Patient-based Forecasting Solution for Pharmaceutical Industry, Mainly for Pipeline Products 3Health News:Amputee Athlete Tells Her Story 2Health News:Amputee Athlete Tells Her Story 3Health News:Amputee Athlete Tells Her Story 4
... Allscripts Executives to Speak at Four Investor Conferences in Coming ... ... Allscripts, the leading,provider of clinical software, connectivity and information solutions that,physicians use ... three months ended March 31, 2008 after the stock,market closes on Wednesday, ...
... the key to transforming healthcare by making medical care more accessible and ... to the following problems that plague patients and practitioners in today,s ... inefficient U.S. healthcare system:, * Doctors are hard ... physician, and nearly one-in-four have problems ...
... Academic Preparedness for, College are Among Challenges Faced ... ... 22 Cengage Learning, one of the,leading providers of print ... library reference markets, today,released survey results highlighting issues first-year college ...
... MONTVALE, N.J., April 22 Primary care clinicians ... health -- bacterial vaginosis,maternal nutritional status, and anemia. ... to work together to raise awareness about,women,s health ... To meet the needs of healthcare providers, The ...
... PAUL, Minn. Monday, April 21, 2008 3M ... than 30 years, today announces plans to introduce the ... designed to deliver reliable, qualitative and objective electronic results ... to the 2008-2009 flu season, the Rapid Detection Flu ...
... SHANGHAI, China, April 22 /Xinhua-PRNewswire-FirstCall/ --,China-Biotics, Inc. (OTC ... firm specializing in the manufacture,research, development, marketing and ... additional Shining(R) retail centers in the,first quarter of ... of 60,stores in six major cities in China., ...
Other Medicine News:Health News:Allscripts to Announce First Quarter 2008 Results on April 30 2Health News:Allscripts to Announce First Quarter 2008 Results on April 30 3Health News:Latest Studies Show Consumer-Directed Telemedicine Solutions Like Consult A Doctor Lower Costs While Providing Greater Access to Affordable, Quality Healthcare. 2Health News:Latest Studies Show Consumer-Directed Telemedicine Solutions Like Consult A Doctor Lower Costs While Providing Greater Access to Affordable, Quality Healthcare. 3Health News:Latest Studies Show Consumer-Directed Telemedicine Solutions Like Consult A Doctor Lower Costs While Providing Greater Access to Affordable, Quality Healthcare. 4Health News:Latest Studies Show Consumer-Directed Telemedicine Solutions Like Consult A Doctor Lower Costs While Providing Greater Access to Affordable, Quality Healthcare. 5Health News:Latest Studies Show Consumer-Directed Telemedicine Solutions Like Consult A Doctor Lower Costs While Providing Greater Access to Affordable, Quality Healthcare. 6Health News:Cengage Learning Survey Reveals College Instructor Views on Challenges Facing First-Year Students 2Health News:Cengage Learning Survey Reveals College Instructor Views on Challenges Facing First-Year Students 3Health News:Cengage Learning Survey Reveals College Instructor Views on Challenges Facing First-Year Students 4Health News:The Women's Health II Medical Education Network Raises Awareness About the Diagnosis and Management of Women's Health Issues 2Health News:3M Health Care announces new 3M Rapid Detection Flu A+B test 2Health News:China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers 2Health News:China-Biotics, Inc. Expands Retail Network to 60 Shining Retail Centers 3
(Date:12/16/2009)... MAQUET Cardiovascular LLC, a leading provider of ... signed a three-year single source provider contract ... company, for MAQUET,s market-leading VASOVIEW Endoscopic Vessel ... healthcare providers in obtaining veins for repair ... incisions. This allows for faster healing, less ...
(Date:12/16/2009)... Inc., a new clinical stage company developing innovative ... on its novel GFPA NMDA receptor modulators, today ... meeting showed that its lead compound GLYX-13 demonstrated ... of the CNS-related side effects seen with other ... also showed that GLYX-13,s antidepressant effects were evident ...
(Date:12/16/2009)... Keryx Biopharmaceuticals, Inc. (Nasdaq: ... a Phase 3 registration clinical trial for ... in relapsed / refractory multiple myeloma patients. ... Randomized Study to Assess the Efficacy and ... of Bortezomib (Velcade®) and Dexamethasone in Multiple ...
Breaking Medicine Technology:MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 2MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 3MAQUET Cardiovascular Awarded Three-Year Single Source Contract From Novation for VASOVIEW Endoscopic Vessel Harvesting Devices 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 2Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 3Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 4Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 5Naurex Inc. Announces Presentation of Preclinical Data Showing its Novel Mechanism NMDA Modulator Exhibits Robust and Rapid-Onset Antidepressant Activity With No Signs of Classic NMDA-Associated Side Effects 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 2Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 3Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 4Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 5Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 6Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma 7Video 3A truth 28R 29 Asks 3A Do You Have What it Takes 3F 47479 1Video 3A truth 28R 29 Asks 3A Do You Have What it Takes 3F 47479 2Video 3A truth 28R 29 Asks 3A Do You Have What it Takes 3F 47479 3Video 3A truth 28R 29 Asks 3A Do You Have What it Takes 3F 47479 4S C BlueCross Makes Coverage Available for Thousands of South Carolina Graduates Lacking Health Insurance 47474 1S C BlueCross Makes Coverage Available for Thousands of South Carolina Graduates Lacking Health Insurance 47474 2Wet ear wax and unpleasant body odors signal breast cancer risk 8673 1Wet ear wax and unpleasant body odors signal breast cancer risk 8673 2
... many challenges in treating patients with cancer, treating ... quite difficult as studies,suggest that certain therapies can ... study prepublished today online in Blood, the official,journal ... treated with,imatinib, a commonly used therapy for chronic ...
... Memory Formula(TM), PURCHASE, N.Y., March 4 ... and marketer of nutritional supplements that,help consumers manage ... address chronic joint pain, today announced the results,of ... 1000 mcg of,chromium, as chromium picolinate, increased brain ...
Other Medicine Technology:Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities 2Leukemia Therapy With Imatinib During Pregnancy May Cause Infant Abnormalities 3New Clinical Data Further Supports Chromium Picolinate's Role in Enhancing Brain Activity in Older Adults 2New Clinical Data Further Supports Chromium Picolinate's Role in Enhancing Brain Activity in Older Adults 3New Clinical Data Further Supports Chromium Picolinate's Role in Enhancing Brain Activity in Older Adults 4
100L...
... is precision, ergonomics, and value!, ... with soft non-slip, contoured handle , ... light plunger spring action , Completely ... without the need for recalibration , ...
Inquire...
... Focus from Thermo Labsystems was ... with uncompromising performance. The ... a custom fit for different ... tip cones allow easier and ...
Medicine Products: